当前位置：药药网 / 药品研发 / 美国药品上市后承诺数据库
Zemaira, Alpha-1-Proteinase Inhibitor (Human)
药品名称
Zemaira, Alpha-1-Proteinase Inhibitor (Human)
承诺描述
Based on the results of the pilot study and the available scientific data at the time that this study is being designed, ZLB Behring will work with entities maintaining registries of alpha1-proteinase inhibitor deficient patients and with the National Institutes of Health (NIH) to design and conduct an adequately-powered study of a clinically meaningful endpoint(s).
承诺状态描述
The final protocol due date has passed with no final protocol received.